Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Clifton Bingham III¹, Yoshiya Tanaka², George Karpouzas³, Tsutomu Takeuchi⁴, Daniel Aletaha⁵, Carter Thorne⁶, Shihong Sheng⁷, Weichun Xu⁷, Ravi Rao⁸, Kaiyin Fei⁷, Benjamin Hsu⁷, Prasheen Agarwal⁷, Sharon Popik⁷, Regina Kurrasch⁹, Steve Peterson⁷, Rita Ganguly⁹, Chenglong Han⁷ and Kelly McQuarrie⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ⁹GlaxoSmithKline, Collegeville, PA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…
Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
Abstract Number: 429 • 2015 ACR/ARHP Annual Meeting
Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴, Carter Thorne⁵, VP Bykerk⁶, Andrew Thompson⁷, Diane Tin⁸ and Deborah Marshall⁹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, St Joseph's Hlth Ctr, London, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada
Background/Purpose: Treatment choices in early rheumatoid arthritis need to balance benefits, risks, and other considerations such as dosing and monitoring. The objective of this study…
Abstract Number: 559 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy
Kevin L. Winthrop¹, Jeffrey R. Curtis², Stephen Lindsey³, Hernan Valdez⁴, Haiyun Fan⁵, Lisy Wang⁶, Alan M. Mendelsohn⁵ and Eustratios Bananis⁵, ¹Oregon Health & Science University, Portland, OR, ²The University of Alabama at Birmingham, Birmingham, AL, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Patients with RA are at increased risk for herpes zoster (HZ). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Treatment…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 1043 • 2015 ACR/ARHP Annual Meeting
Enhancing Comparative Effectiveness Research By Combining Observational and Randomized Trial Data to Personalize the Choice Between Methotrexate and Triple Therapy for Methotrexate-Naïve Patients with Early Rheumatoid Arthritis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, Gilles Boire⁴, Carol Hitchon⁵, Edward C. Keystone⁶, Boulos Haraoui⁷, J Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Daming Lin¹¹, VP Bykerk¹² and CATCH investigators, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Institut de Rhumatologie, Montreal, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for comparing efficacy of treatments, but the results may be less generalizable to clinical practice…
Abstract Number: 2318 • 2015 ACR/ARHP Annual Meeting
Inflammatory Arthritis Patient Perspectives on Strategies to Support Medication Adherence: A Qualitative Study Using a Novel Group Exercise
Sharan K. Rai¹, Pavandeep Mehat², Anne Townsend³, Carlo Marra⁴, Harpreet Chhina⁵, Rhonda Shuckett⁶ and Mary A. De Vera², ¹Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Medical School, University of Exeter, Exeter, United Kingdom, ⁴School of Pharmacy, Memorial University, St. John's, NF, Canada, ⁵Orthopedic Surgery, BC Children's Hospital, Vancouver, BC, Canada, ⁶Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Disappointing and inconsistent findings of adherence intervention research in inflammatory arthritis (IA) highlight the need for further work in designing interventions that promote and…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 2725 • 2015 ACR/ARHP Annual Meeting
Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States
Rishi J. Desai¹, Daniel H. Solomon², Jun Liu³ and Seoyoung C. Kim⁴, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Treatment of rheumatoid arthritis (RA) with disease modifying anti-rheumatic drugs (DMARDs) has undergone major advances in last two decades. More than 10 non-biologic DMARDs…
Abstract Number: 2967 • 2014 ACR/ARHP Annual Meeting
Patient Reported Pain By the Paindetect Questionnaire Reveals Multimodal Elements to Pain Perception in Rheumatoid Arthritis
Saqa Ahmed¹, Tejal Magan¹, Mario Vargas¹, Abiola Harrison¹ and Nidhi Sofat², ¹Rheumatology, Mailpoint J1A, St George's, University of London, London, United Kingdom, ²Rheumatology, St. George's University of London, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted towards synovial joints. Inhibition of pro-inflammatory networks by disease-modifying anti-rheumatic drugs…
Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, G. Akdemir¹, H.K Ronday², T.H.E. Molenaar³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, I. Speyer⁶, G. Collee⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 343 • 2013 ACR/ARHP Annual Meeting
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Elisabeth Lie¹, Karen M. Fagerli¹, Erik Rødevand², Synnøve Kalstad³, Knut Mikkelsen⁴, Ada Wierød⁵, Désirée van der Heijde⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ³Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁴Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital Drammen, Drammen, Norway, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Methotrexate (MTX), sulfasalazine (SSZ) and leflunomide (LEF) are recommended treatments for PsA patients with active peripheral arthritis. In the publication of a recent negative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].